Business Context and Reporting Period
This Form 8-K reports on the results of the 2025 Annual Meeting of Stockholders held by Prime Medicine, Inc. on June 4, 2025. The meeting was conducted virtually via live webcast. As of the record date (April 8, 2025), there were 131,160,842 shares of Common Stock outstanding and entitled to vote.
Key Financial Metrics
This filing is a Current Report regarding corporate governance and does not contain financial performance data. The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
No material financial changes are reported in this document. The filing details the successful ratification of corporate governance proposals, including the election of directors and the appointment of the independent auditor.
Guidance, Outlook, and Management Commentary
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of risks and contingencies. The primary focus is the disclosure of voting results for two proposals:
- Proposal 1: Election of Class III Directors Thomas Cahill, M.D., Ph.D., and Robert Nelsen.
- Proposal 2: Ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Investor Verification Checklist
- Voting Participation: Verify that 98,093,739 shares were present or represented by proxy, establishing a quorum.
- Director Election Results: Confirm Thomas Cahill received 74,446,103 "For" votes and Robert Nelsen received 70,607,668 "For" votes.
- Auditor Ratification: Note that PricewaterhouseCoopers LLP was ratified with 98,008,974 "For" votes against 42,555 "Against" votes.
- Broker Non-Votes: Observe that 15,311,067 shares were recorded as broker non-votes for the director elections.